

## **CURRICULUM VITAE**

**Paul J. Brett, Ph.D.**

Department of Microbiology and Immunology  
University of Nevada, Reno School of Medicine  
1664 N. Virginia Street, CMM L-311B  
Reno, NV 89557  
Email: pbrett@med.unr.edu

**NATIONALITY:** Canadian

**RESIDENCY STATUS:** U.S. Permanent Resident

### **EDUCATION:**

1998 Ph.D. Bacterial Pathogenesis  
Department of Microbiology and Infectious Diseases  
University of Calgary  
Calgary, AB, Canada  
Supervisor: Dr. Donald E. Woods  
Dissertation: Immunoprophylaxis Against Melioidosis.

1993 B.Sc. Biochemistry  
(with distinction) University of Victoria  
Victoria, BC, Canada

### **EMPLOYMENT HISTORY:**

07/2017 - present Associate Professor (with tenure)  
Department of Microbiology and Immunology  
University of Nevada, Reno School of Medicine  
Reno, NV, USA

08/2014 - 06/2017 Associate Professor (with tenure)  
Department of Microbiology and Immunology  
University of South Alabama, College of Medicine  
Mobile, AL, USA

08/2013 - 07/2014 Associate Professor (tenure track)  
Department of Microbiology and Immunology  
University of South Alabama, College of Medicine  
Mobile, AL, USA

11/2008 - 07/2013      Assistant Professor (tenure track)  
 Department of Microbiology and Immunology  
 University of South Alabama, College of Medicine  
 Mobile, AL, USA

09/2003 - 09/2008      Visiting Fellow  
 Laboratory of Zoonotic Pathogens  
 Rocky Mountain Laboratories, NIAID, NIH  
 Hamilton, MT, USA

01/2002 - 08/2003      Research Scientist II and Project Leader  
 Quorex Pharmaceuticals, Inc.  
 Carlsbad, CA, USA

05/2001 - 12/2001      Research Scientist I  
 Quorex Pharmaceuticals, Inc.  
 Carlsbad, CA, USA

04/2000 - 04/2001      Postdoctoral Fellow  
 Department of Microbiology and Infectious Diseases  
 University of Calgary  
 Calgary, AB, Canada

01/1999 - 03/2000      Postdoctoral Fellow  
 Department of Medical Microbiology  
 University College London  
 London, United Kingdom

#### **AWARDS AND DISTINCTIONS:**

2020      Visiting Associate Professor. Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand.

2019      Co-chair Vaccines and Prevention session. 9<sup>th</sup> World Melioidosis Congress. Hanoi, Vietnam.

2019      Keynote Speaker. VALIDATE-BSI 2019 Conference. London, England.

2019      Jenner Seminar Speaker. The Jenner Institute. Oxford, UK.

2016      Co-chair Immunology 2 session. 8<sup>th</sup> World Melioidosis Congress. Cebu, Philippines.

2013      Poster Award - Immunology and Vaccines. 7<sup>th</sup> World Melioidosis Congress. Bangkok, Thailand.

- 2013 Poster Award - Epidemiology, Veterinary Aspects and Clinical Laboratory Diagnosis. 7<sup>th</sup> World Melioidosis Congress. Bangkok, Thailand.
- 2012 Inaugural Donald E. Woods Young Investigator Lecturer. Banff Conference on Infectious Diseases, Banff, AB, Canada
- 1997 - 1998 Alberta Heritage Foundation for Medical Research Full-Time Studentship
- 1997 - 1998 William H. Davies Scholarship
- 1997 Canadian Society for Microbiologists Graduate Student Microbiologist of the Year Competition - 2<sup>nd</sup> Place

### **TEACHING EXPERIENCE:**

- 2020 - present Microbes and Society (MICR 100)
- 2020 - present Medical Microbiology (MICR 300)
- 2020 - present Cellular and Molecular Biology of Tropical Diseases (TMID 534)
- 2020 Explorations in Microbiology (MICR 484)
- 2020 - present Molecular Cell Biology (CMB 710)
- 2019 - present Comprehensive Exam (CMB 795)
- 2018 - present Dissertation (CMB 799)
- 2018 - present Research (BIOT 447)
- 2018 - present Independent Study (CMB 793 and MICR 793)
- 2018 - present Foundations and Principles of Medical Science II (MED 636 - Block 6)
- 2017 - present Lab Practicum I (CMB 701), Lab Practicum II (CMB 702), Lab Practicum III (CMB 703)
- 2015 - 2017 Infectious Disease and Host Defense (IHD 120)
- 2014 - 2017 Microbes and Host Defense (MIC 530)
- 2014 - 2017 Advanced Microbial Pathogenesis (MIC 630)
- 2013 - 2014 Hematology and Host Defense (HHD 120)

2012	Foundations of Human Health (FHH 110)
2011	Diversity Recruitment and Enrichment for Admission into Medicine (DREAM) Program: Phase I - Microbiology
2010 - 2017	Fundamentals of Basic Medical Science II (IDL 581)
2010 - 2014	Literature Reports (IDL 576)
2010 - 2011	Medical Microbiology and Immunology Lab (MIC 211/530)
2010	Microbial Physiology, Genetics and Pathogenesis (MIC 630)
2009 - 2012	Medical Microbiology and Immunology (MIC 211/530)
2004 - 2007	Biomedical Research After-School Scholars Series Ravalli County School District, MT, USA
1996 - 1997	Graduate Teaching Assistant (Medical Microbiology MDSC 612) University of Calgary, Calgary, AB, Canada

#### **MENTORING EXPERIENCE:**

2019 - 2020	Microbiology and Immunology Student Volunteer: Calvin Chan
2019	Postdoctoral Fellow: Dr. Vichaya Suttisunhakul
2018 - present	Tropical Medicine (International Program) graduate student (Thailand): Apinya Pumpuang
2018 - present	Cellular Molecular Biosciences graduate student: Caitlyn Orne
2018 - 2019	Molecular Microbiology and Immunology Studentship: James Pazar
2018	Molecular Microbiology and Immunology Studentship: Avneet Chhabra
2017 - present	Cellular Molecular Biosciences graduate student: Lindsey Schmidt
2016	Visiting Student (Thailand): Sirikamon Koosakulnirand
2014 - 2017	Postdoctoral Fellow: Dr. Teresa Shaffer
2014 - 2015	Pulmonary Resident: Dr. Zakiya Douglas
2014	Basic Medical Sciences graduate student rotation: Dustin Chalker

2013 - 2014      Basic Medical Sciences graduate student rotation: Joshua Stone

2013              Basic Medical Sciences graduate student rotation: Kevin Abney

2012              Basic Medical Sciences graduate student rotation: Kathleen McClinton

2009              Summer Medical Student Research program: Brian Fletcher

**UNIVERSITY SERVICE:**

2020 - present      Laboratory Safety Committee - Member

2020 - present      UNR Institutional Biosafety Committee - Chair

2020 - present      UNR Institutional Animal Care and Use Committee - Vice Chair

2019 - present      UNR Med Promotion and Tenure Committee - Member

2019 - 2020        UNR Institutional Animal Care and Use Committee - Member

2018 - 2019        UNR Institutional Animal Care and Use Committee - Alternate

2015 - 2017        Laboratory of Infectious Diseases - Associate Facility Director

2014 - 2017        Laboratory of Infectious Diseases Safety Committee - Chair

2014 - 2017        USA Institutional Animal Care and Use Committee - Member

2014 - 2017        Dissertation Committee: Brandon D'Arcy - Department of Biochemistry

2013 - 2017        Basic Medical Sciences Graduate Executive Committee

2013 - 2017        Dissertation Committee: Andrew Ferretti - Department of Microbiology and Immunology

2013 - 2017        Dissertation Committee: Kathleen McClinton - Department of Pharmacology

2013                Responsible Conduct in Research - Facilitator

2012 - 2017        Basic Medical Sciences Infectious Disease and Host Defense - Track Director

2012                USA Institutional Animal Care and Use Committee - Chair

2012 - 2013	College of Medicine Student Research Committee - Member
2010 - 2012	Dissertation Committee: Todd Smith - Department of Microbiology and Immunology
2011 - 2012	USA Institutional Animal Care and Use Committee - Vice Chair
2010 - 2016	College of Medicine BioImaging Facility Advisory Board - Member
2010	Liaison Committee on Medical Education - Subcommittee Member
2010	Responsible Conduct in Research - Facilitator
2009 - 2015	Laboratory of Infectious Diseases Committee - Member
2009 - 2011	USA Institutional Animal Care and Use Committee - Member
2009 - 2017	College of Medicine Research Forum Committee - Member

**PROFESSIONAL SERVICE:**

2020	Chair: Tanes Sangsri Virtual Dissertation Defense (Bangkok, Thailand)
2018 - present	Subject matter expert: Defense Threat Reduction Agency Chemical and Biological Defense Program
2017	Promotion and tenure reviewer: University of Exeter
2017	Promotion and tenure reviewer: University of Tennessee Health Science Center
2016	Peer Reviewer: Defense Threat Reduction Agency's Basic Research for Combating Weapons of Mass Destruction Program (PerF - Topic 12)
2016 - 2017	International collaborator: Newton Fund Institutional Links (Thailand)
2015 - 2020	Consultant: Roche Diagnostics - Myanmar
2015	International collaborator: Thai-Bacterial Infection Research and Training Network
2015 - 2017	Dissertation committee member: Laura Muruato - Department of Microbiology and Immunology, UTMB, Galveston, TX

- 2013 - 2015      Committee member: Steering Group on Melioidosis Vaccine Development (SGMVD)
- 2013              Ad hoc grant reviewer: NIH Vaccines Against Microbial Diseases (VMD) study section
- 2012 - 2013      Subject matter expert/consultant: Southern Research Institute
- 2012              Ad hoc grant reviewer: The Deutsche Forschungsgemeinschaft (The German Research Foundation)
- 2012              Invited speaker: Rocky Mountain Laboratories Fellows Organization Career Seminar Series
- 2011              Ph.D. thesis external examiner: Cameron Flegg - School of Medical Science and Institute for Glycomics, Griffith University, QLD, Australia
- 2011              Panel member: 4<sup>th</sup> Annual NIH Career Symposium - Faculty Careers in Research-Intensive Schools
- 2010              Ad hoc grant reviewer: United Kingdom Medical Research Council Infections and Immunity Board (t-IIB)
- 2010              Review panel member: NIH Partnerships for Biodefense (RFA-AI-10-003)
- 2010              Review panel member: NIH Protective Immunity in Special Populations (BAA-NIHAI2010085)
- 2010              Subject matter expert: National Biodefense Analysis and Countermeasures Center Department of Homeland Security Bioterrorism Threat Risk Assessment review
- 2010              Review panel member: Joint Science and Technology Office for Chemical and Biological Defense, Basic and Supporting Sciences Division, Medical Basic Research Capability Area, FY10 Science Review
- 2010              Ad hoc grant reviewer: Defense Threat Reduction Agency Chemical and Biological Defense Program
- 2009              Review panel member: Joint Science and Technology Office for Chemical and Biological Defense, Basic and Supporting Sciences Division, Medical Basic Research Capability Area, FY09 Science Review
- 2009              Ad hoc grant reviewer: Defense Threat Reduction Agency Chemical and Biological Defense Program

2009 Ad hoc grant reviewer: American Heart Association Region 1, Basic Cell

### **Journals:**

2014 - 2019 Editorial Board: Infection and Immunity

2014 Invited Editor: mBio

2008 - present Ad hoc reviewer: Alabama Academy of Sciences, The American Journal of Pathology, Antimicrobial Agents and Chemotherapy, Applied and Environmental Microbiology, BMC Microbiology, BMC Veterinary Research, Cellular Immunology, Central European Journal of Biology, Clinical Microbiology Reviews, Clinical and Vaccine Immunology, FEMS Immunology and Medical, Microbiology, FEMS Microbiology Letters, Frontiers in Cellular and Infection Microbiology, Infection and Immunity, Innate Immunity, Journal of Bacteriology, Journal of Clinical Microbiology, Journal of Proteome Research, mBio, Microbial Pathogenesis, Microbiology, Molecular Microbiology, Nature Scientific Reports, PLoS Neglected Tropical Diseases, NPJ Vaccines, PLoS One, PLoS Pathogens, Proteomics, Tropical Medicine and Infectious Disease, Vaccine.

### **PUBLIC SERVICE:**

2017 Science Café, NV (October 2): Melioidosis - An Important but Little Known Tropical Disease.

### **PROFESSIONAL AFFILIATIONS:**

2018 - present VALIDATE Network

2017 - present American Society for Hygiene and Tropical Medicine

1993 - present American Society for Microbiology

### **PUBLICATIONS:**

#### **Peer-Reviewed Manuscripts:**

1. Pumpuang, A., Phunpang, R., Ekchariyawat, P., Dulsuk, A., Loupha, S., Kwawong, K., Charoensawat, Y., Thiansukhon, E., Day, N.P.J., Burtnick, M.N., **Brett, P.J.**, West, T.E., Chantratita, N. 2019. Distinct Classes and Subclasses of Antibodies to Hemolysin Co-



Regulated Protein 1 and O-Polysaccharide and Correlation with Clinical Characteristics of Melioidosis Patients. *Sci Rep.* **9**:13972. PMID: 31562344.

2. Cloutier, M., Delar, E., Muru, K., Ndong, S., Hoyeck, R.R., Kaewarpai, T., Chantratita, N., Burtnick, M.N., **Brett, P.J.**, Gauthier, C. 2019. Melioidosis Patient Serum-Reactive Synthetic Tetrasaccharides Bearing the Predominant Epitopes of *Burkholderia pseudomallei* and *Burkholderia mallei* O-antigens. *Org Biomol Chem.* **17**:8878-8901. PMID: 31513223.
3. Schully, K.L., Burtnick, M.N., Bell, M.G., Spall, A., Mayo, M., Rigas, V., Chan, A.A., Yu, K., Clark, D.V., Maves, R.C., Currie, B.J., **Brett, P.J.**, Lawler, J.V. 2019. Serological Evidence of *Burkholderia pseudomallei* Infection in U.S. Marines Who Trained in Australia from 2012-2014: A Retrospective Analysis of Archived Samples. *MSMR.* **26**:8-17. PMID: 31347371.
4. Yi, J., Simpanya, M.F., Settles, E.W., Shannon, A.B., Hernandez, K., Pristo, L., Keener, M.E., Hornstra, H., Busch, J.D., Soffler, C., **Brett, P.J.**, Currie, B.J., Bowen, R.A., Tuanyok, A., Keim, P. 2019. Caprine Humoral Response to *Burkholderia pseudomallei* Antigens During Acute Melioidosis from Aerosol Exposure. *PLoS Negl Trop Dis.* 2019. **13**:e0006851. PMID: 30811382.
5. Koosakulnirand, S., Phokrai, P., Jenjaroen, K., Roberts, R.A., Utaisincharoen, P., Dunachie, S.J., **Brett, P.J.**, Burtnick, M.N. and Chantratita, N. 2018. Immune Response to Recombinant *Burkholderia pseudomallei* FliC. *PLoS One.* **13**:e0198906. PMID: 29902230.
6. Phokrai, P., Karoonboonyanan, W., Thanapattarapairoj, N., Promkong, C., Dulsuk, A., Koosakulnirand, S., Canovali, S., Indrawattana, N., Jutrakul, Y., Wuthiekanun, V., Limmathurotsakul, D., **Brett, P.J.**, Burtnick, M.N., Lertmemongkolchai, G. and Chantratita N. 2018. A Rapid Immunochromatography Test Based on Hcp1 is a Potential Point-of-Care Test for Serological Diagnosis of Melioidosis. *J Clin Microbiol.* **56**. e00346-18. PMID: 29848565.
7. Win, Z.Z., Phokrai, P., Aung, Z., Zaw, T., Burtnick, M.N., Chantratita, N., **Brett, P.J.** and Hlaing, T.M. 2018. Use of Rapid ELISAs for Serological Screening of Melioidosis in Myanmar. *Am J Hyg Trop Med.* **98**:1300-1302. PMID: 29557332.
8. Suttisunhakul, V., Hip, P., Ouch, P., Ly, P., Supaprom, C., Rachmat, A., Prouty, M., Vaughn, A., Eltayeb, A., Kheng, S., Clark, D.V., Lawler, J.V., Chantratita, N., Burtnick, M.N., **Brett, P.J.** and Schully, K.L. 2018. Retrospective Analysis of Fever and Sepsis Patients from Cambodia Reveals Serological Evidence of Melioidosis. *Am J Hyg Trop Med.* **98**:1039-1045. PMID: 29436341.
9. Burtnick, M.N., Shaffer, T.L., Ross, B.N., Muruato, L.A., Sbrana, E., DeShazer, D., Torres, A.G. and **Brett, P.J.** 2017. Development of Subunit Vaccines that Provide High

- Level Protection and Sterilizing Immunity Against Acute Inhalational Melioidosis. *Infect Immun.* **86**:e00724-17. PMID: 29109172.
10. Muruato, L.A., Tapia, D., Hatcher, C.L., Kalita, M., **Brett, P.J.**, Gregory, A.E., Samuel, J.E., Titball, R.W. and Torres, A.G. 2017. The Use of Reverse Vaccinology in the Design and Construction of Nano-glycoconjugate Vaccines against *Burkholderia pseudomallei*. **24**: Clin Vaccine Immunol. e00206-17. PMID: 28903988.
  11. Tamigney Kenfack, M., Mazur, M., Nualnoi, T., Shaffer, T.L., Ngassimou, A., Blériot, Y., Marrot, J., Marchetti, R., Sintiprungrat, K., Chantratita, N., Silipo, A., Molinaro, A., AuCoin, D.P., Burtnick, M.N., **Brett, P.J.** and Gauthier, C. 2017. Deciphering Minimal Antigenic Epitopes Associated with *Burkholderia pseudomallei* and *Burkholderia mallei* Lipopolysaccharide O-antigens. *Nature Comm.* **8**:115. PMID: 28740137.
  12. Borlee, G.I., Plumley, B.A., Martin, K.H., Somprasong, N., Mangalea, M.R., Islam, M.N., Burtnick, M.N., **Brett, P.J.**, Steinmetz, I., AuCoin, D.P., Belisle, J.T., Crick, D., Schweizer, H.P. and Borlee, B.R. 2017. Genome-scale Analysis of the Genes that Contribute to *Burkholderia pseudomallei* Biofilm Formation Identifies a Crucial Exopolysaccharide Biosynthesis Gene Cluster. *PLoS Negl Trop Dis.* **11**:e0005689. PMID: 28658258.
  13. Chaichana, P., Chantratita, N., Brod, F., Koosakulnirand, S., Jenjaroen, K., Chumseng, S., Sumonwiriya, M., Burtnick, M.N., **Brett, P.J.**, Teparrukkul, P., Limmathurotsakul, D., Day, N.P.J., Dunachie, S.J. and West, T.E. 2017. A Nonsense Mutation in TLR5 is Associated with Survival and Reduced IL-10 and TNF- $\alpha$  Levels in Human Melioidosis. *PLoS Negl Trop Dis.* **11**:e0005587. PMID: 28475641.
  14. Pumpuang, A., Dunachie, S.J., Phokrai, P., Jenjaroen, K., Sintiprungrat, K., Boonsilp, S., **Brett, P.J.**, Burtnick, M.N. and Chantratita, N. 2017. Comparison of O-polysaccharide and Hemolysin Co-regulated Protein as Target Antigens for Serodiagnosis of Melioidosis. *PLoS Negl Trop Dis.* **11**:e0005499. PMID: 28358816.
  15. Titball, R.W., Burtnick, M.N., Bancroft, G.J. and **Brett, P.** 2017. *Burkholderia pseudomallei* and *Burkholderia mallei* vaccines: Are We Close to Clinical Trials? *Vaccine.* pii: S0264-410X(17)30328-6. PMID: 28336210.
  16. Nualnoi, T., Norris, M.H., Tuanyok, A., **Brett, P.J.**, Burtnick, M.N., Keim, P.S., Settles, E.W., Allender, C.J. and AuCoin, D.P. 2017. Development of Immunoassays for *Burkholderia pseudomallei* Typical and Atypical Lipopolysaccharide Strain Typing. *Am J Trop Med Hyg.* **96**:358-367. PMID: 27994103.
  17. Plumley, B.A., Martin, K.H., Borlee, G.I., Marlenee, N.L., Burtnick, M.N., **Brett, P.J.**, AuCoin, D.P., Bowen, R.A., Schweizer, H.P. and Borlee, B.R. 2017. Thermoregulation of Biofilm Formation in *Burkholderia pseudomallei* is Disrupted by Mutation of a Putative Diguanylate Cyclase. *J Bacteriol.* **199**:pii: e00780-16. PMID: 27956524.

18. Nualnoi, T., Kiroosingh, A., Pandit, S.G., Thorkildson, P., **Brett, P.J.**, Burtnick, M.N. and AuCoin, D.P. 2016. In vivo Distribution and Clearance of Purified Capsular Polysaccharide from *Burkholderia pseudomallei* in a Murine Model. *PLoS Negl Trop Dis.* **10**:e0005217. PMID: 27941991.
19. Chua, J., Senft, J., Lockett, S., **Brett, P.J.**, Burtnick, M.N., Deshazer, D. and Friedlander, A. 2016. pH Alkalinization by Chloroquine Suppresses Pathogenic *Burkholderia* T6SS-1 and Multi-Nucleated Giant Cells. *Infect Immun.* **85**:e00586-16. PMID: 27799332.
20. Dillon, M.J., Loban, R.A., Reed, D.E., Thorkildson, P., **Brett, P.J.**, Burtnick, M.N., Bowen, R.A. and AuCoin, D.P. 2016. Contribution of Murine IgG Fc Regions to Antibody Binding to the Capsule of *Burkholderia pseudomallei*. *Virulence.* **20**:1-11. PMID: 27096636.
21. Suttisunhakul, V., Wuthiekanun, V., **Brett, P.J.**, Day, N.P., Burtnick, M.N., Limmathurotsakul, D. and Chantratita, N. 2016. Development of rapid ELISAs for detection of antibodies to *Burkholderia pseudomallei*. *J Clin Microbiol.* **54**:1259-68. PMID: 26912754.
22. Marchetti, R., Dillon, M., Burtnick, M.N., Tamigney-Kenfack, M., Bleriot, Y., Lanzetta, R., Gauthier, C., **Brett, P.**, AuCoin, D., Silipo, A. and Molinaro, A. 2015. *Burkholderia pseudomallei* Capsular Polysaccharide Recognition by a Monoclonal Antibody Reveals Key Details Toward a Biodefense Vaccine and Diagnostics Against Melioidosis. *ACS Chem Biol.***10**:2295-302. PMID: 26198038.
23. Suttisunhakul, V., Chantratita, N., Wikraiphath, C., Wuthiekanun, V., Douglas, Z., Day, N.P.J., Limmathurotsakul, D., **Brett, P.J.** and Burtnick, M.N. 2015. Evaluation of Polysaccharide-Based Latex Agglutination Assays for the Rapid Detection of Antibodies to *Burkholderia pseudomallei*. *Am J Hyg Trop Med.* **93**:542-6. PMID: 26123956.
24. Limmathurotsakul, D., Funnell, S., Torres, A.G., Morici, L.A., **Brett, P.J.**, Dunnachie, S., Atkins, T., Altmann, D.M., Bancroft, G. and Peacock, S.J. 2015. Consensus on the Development of Melioidosis Vaccines for Naturally Acquired Infection. *Emerg Infect Dis.* **21**. PMID: 25992835.
25. Wikraiphath, C., Saiprom, N., Tandhavanant, S., Heiss, C., Azadi, P., Wongsuvan, G., Tuanyok, A., Holden, M.T., Burtnick, M.N., **Brett, P.J.**, Peacock, S.J. and Chantratita, N. 2015. Colony Morphology Variation of *Burkholderia pseudomallei* Is Associated with Antigenic Variation and O-Polysaccharide Modification. *Infect Immun.* **83**:2127-38. PMID: 25776750.

26. Hoffmaster, A., AuCoin., D, Baccam, S., Baggett, H., Baird, R., Bhengsi, S., Blaney, D., Boonmar, S., **Brett, P.**, Brooks, T., Brown, K., Chantratita, N., Cheng, A., Dance, D., Decuyper, S., Defenbaugh, D., Dixon, D., Gee, J., Houghton, R., Jorakate, P., Lertmemongkolchai, G., Limmathurotsakul, D., Merlin, T., Mukhopadhyay, C., Mukhopadhyay, S., Norton, R., Peacock, S., Pickett, T., Rolim, D., Simpson, A., Steinmetz, I., Stoddard, R., Stokes, M., Sue, D., Tuanyok, A., Whistler, T., Wuthiekanun, V. and Walke, H. 2015. Melioidosis Diagnostic Workshop, Diagnostic Gaps in Endemic and Non-endemic Areas. *Emerg Infect Dis.* **21**. PMID: 25626057.
27. Stone, J.K., Deshazer, D., **Brett, P.J.** and Burtnick, M.N. 2014. Melioidosis: Molecular Aspects of Pathogenesis. *Expert Rev Anti Infect Ther.* **14**:1-13. PMID: 25312349.
28. Burtnick, M.N., **Brett, P.J.** and DeShazer D. 2014. Proteomic Analysis of the *Burkholderia pseudomallei* Type II Secretome Reveals Hydrolytic Enzymes, Novel Proteins and the Deubiquitinase TssM. *Infect Immun.* **82**:3214-26. PMID: 24866793.
29. Scott, A.E., Burtnick, M.N., Stokes, M.G., Whelan, A.O., Williamson, E.D., Atkins, T.P., Prior, J.L. and **Brett, P.J.** 2014. *Burkholderia pseudomallei* capsular polysaccharide conjugates provide protection against acute melioidosis. *Infect Immun.* **82**:3206-13. PMID: 24866807.
30. Houghton, R.L., Reed, D.E., Hubbard, M.A., Dillon, M.J., Raychaudhuri, S., Chen, H., Currie, B.J., Mayo, M., Sarovich, D.S., Theobald, V., Limmathurotsakul, D., Chantratita, N., Peacock, S.J., Hoffmaster, A.R., Duval, B., **Brett, P.J.**, Burtnick, M.N. and AuCoin, D.P. 2014. Development of a Prototype Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis. *PLoS Negl Trop Dis.* **8**:e2727. PMID: 24651568.
31. Burtnick, M.N. and **Brett, P.J.** 2013. *Burkholderia mallei* and *Burkholderia pseudomallei* T6SS-1 Gene Expression is Negatively Regulated by Divalent Cations. *PLoS One.* **11**:e76767. PMID: 24146925.
32. Heiss, C., Burtnick, M.N., Roberts, R.A., Black, I., Azadi, P. and **Brett, P.J.** 2013. Revised Structures for the Predominant O-polysaccharides Expressed by *Burkholderia pseudomallei* and *Burkholderia mallei*. *Carbohydr Res.* **381**:6-11. PMID: 24056008.
33. Burtnick, M.N., Heiss, C., Schuler, A.M., Azadi, P. and **Brett, P.J.** 2012. Development of Novel O-Polysaccharide Based Glycoconjugates for Immunization Against Glanders. *Front Cell Infect Microbiol.* **2**:148. PMID: 23205347.
34. Heiss, C., Burtnick, M.N., Black, I., Azadi, P. and **Brett, P.J.** 2012. Detailed Structural Analysis of the O-Polysaccharide Expressed by *Burkholderia thailandensis* E264. *Carbohydr Res.* **363**:23-28. PMID: 23103510.
35. Burtnick, M.N., Heiss, C., Roberts, R.A., Scheiwzer, H.P., Azadi, P. and **Brett, P.J.** 2012. Development of Capsular Polysaccharide-Based Glycoconjugates for Immunization Against Melioidosis and Glanders. *Front Cell Infect Microbiol.* **2**:108. PMID: 22912938.

36. Heiss, C., Burtnick, M.N., Wang, Z., Azadi, P. and **Brett, P.J.** 2012. Structural Analysis of Capsular Polysaccharides Expressed by *Burkholderia mallei* and *Burkholderia pseudomallei*. *Carbohydr Res.* **349**:90-94. PMID: 22221792.
37. Nuti, D.E., Crump, R.B., Handayani, F.D., Chantratita, N., Peacock, S.J., Bowen, R., Felgner, P.L., Davies, D.H., Wu, T., Lyons, C.R., **Brett, P.J.**, Burtnick, M.N., Kozel, T.R. and AuCoin, D.P. 2011. Identification of Circulating Bacterial Antigens by In vivo Microbial Antigen Discovery. *mBio.* **2**:e00136-11. PMID: 21846829.
38. Burtnick, M.N., **Brett, P.J.**, Harding, S.V., Ngugi, S., Ribot, W.J., Chantratita, N., Scorpio, A., Milne, T.S., Dean, R., Fritz, D.L., Peacock, S.J., Prior, J.L., Atkins, T.P. and DeShazer, D. 2011. The Cluster 1 Type VI Secretion System is a Major Virulence Determinant in *Burkholderia pseudomallei*. *Infect Immun.* **79**:1512-1575. PMID: 21300775.
39. **Brett, P.J.**, Burtnick, M.N., Heiss, C., Azadi, P., DeShazer, D., Woods, D.E. and Gherardini, F.C. 2011. *Burkholderia thailandensis oacA* Mutants Facilitate the Expression of *Burkholderia mallei*-like O-Polysaccharides. *Infect Immun.* **79**:961-969. PMID: 21115721.
40. Galyov, E.E., **Brett, P.J.** and DeShazer, D. 2010. Molecular Insights into *Burkholderia pseudomallei* and *Burkholderia mallei* Pathogenesis. *Annu Rev Microbiol.* **64**:495-517. PMID: 20528691.
41. Burtnick, M.N., Deshazer, D., Nair V., Gherardini, F.C. and **Brett, P.J.** 2010. *Burkholderia mallei* Cluster 1 Type VI Secretion Mutants Exhibit Growth and Actin-Motility and Defects in RAW 264.7 Murine Macrophages. *Infect Immun.* **78**:88-99. PMID: 19884331.
42. Shanks, J., Burtnick, M.N., **Brett, P.J.**, Waag, D.M., Spurgers, K., Ribot, W.J., Schell, M.A., Panchal, R.G., Gherardini, F.C., Wilkinson, K.D. and DeShazer, D. 2009. *Burkholderia mallei tssM* Encodes a Secreted Deubiquitinase That Is Expressed Inside Infected RAW 264.7 Cells. *Infect Immun.* **77**:1636-1648. PMID: 19168747.
43. **Brett, P.J.**, Burtnick, M.N., Fenno, J.C. and Gherardini, F.C. 2008. *Treponema denticola* TroR is a Manganese- and Iron-Dependent Transcriptional Repressor. *Mol Microbiol.* **70**:396-409. PMID: 18761626.
44. Burtnick, M.N., **Brett, P.J.**, Nair, V., Warawa, J.M., Woods D.E. and Gherardini, F.C. 2008. *Burkholderia pseudomallei* Type III Secretion System Mutants Exhibit Delayed Vacuolar Escape Phenotypes in RAW 264.7 Murine Macrophages. *Infect Immun.* **76**:2991-3000. PMID: 18443088.
45. **Brett, P.J.**, Burtnick, M.N., Su, H., Nair, V. and Gherardini, F.C. 2008. iNOS Activity is Critical for the Clearance of *Burkholderia mallei* from Infected RAW 264.7 Murine Macrophages. *Cell Microbiol.* **10**:487-498. PMID: 17970762.

46. Burtnick, M.N., Downey, J.S., **Brett, P.J.**, Boylan, J.A., Frye, J.G., Hoover, T.R. and Gherardini, F.C. 2007. Insights into the complex regulation of *rpoS* in *Borrelia burgdorferi*. *Mol Microbiol.* **65**:277-293. PMID: 17590233.
47. **Brett, P.J.**, Burtnick, M.N., Snyder, D.S., Shannon J.G., Azadi, P. and Gherardini, F.C. 2007. *Burkholderia mallei* Expresses a Unique Lipopolysaccharide Mixture that is a Potent Activator of Human Toll-like Receptor 4 Complexes. *Mol Microbiol.* **63**:379-390. PMID: 17163980.
48. **Brett, P.J.**, Burtnick, M.N. and Woods, D.E. 2003. The *wbiA* Locus is Required for 2-O-Acetylation of Lipopolysaccharides Expressed by *Burkholderia pseudomallei* and *Burkholderia thailandensis*. *FEMS Microbiol Lett.* **218**:323-328. PMID: 12586411.
49. **Brett, P.J.**, Tiwana, H., Feavers, I.M. and Charalambous, B.M. 2002. Characterization of Oligopeptides That Cross-React with Carbohydrate-Specific Antibodies by Real-Time Kinetic, In-Solution Competition ELISA and Immunological Analyses. *J Biol Chem.* **277**:20468-20476. PMID: 11923297.
50. Burtnick, M.N., **Brett, P.J.** and Woods, D.E. 2002. Molecular and Physical Characterization of *Burkholderia mallei* O-Antigens. *J Bacteriol.* **184**:849-852. PMID: 12491898.
51. Burtnick, M.N., Bolton, A.J., **Brett, P.J.**, Watanabe, D. and Woods, D.E. 2001. Identification of the Acid Phosphatase (*acpA*) Gene Homologues in Pathogenic and Non-Pathogenic *Burkholderia* spp. Facilitates *TnphoA* Mutagenesis. *Microbiol.* **147**:111-120. PMID: 11790757.
52. **Brett, P.J.** and Woods, D.E. 2000. Pathogenesis of and Immunity to Melioidosis. *Acta Trop.* **74**:201-210. PMID: 10674650.
53. Charuchaimongkol, C., Suputtamogkol, Y., Nilakul, C., Chaowagul, W., Chetchotisakd, P., Lertpatanasuwun, N., Intaranongpai, S., **Brett, P.J.** and Woods, D.E. 1999. Antilipopolysaccharide II: An Antibody Protective Against Fatal Melioidosis. *Clin Infect Dis.* **29**:813-818. PMID: 10589895.
54. DeShazer, D., **Brett, P.J.**, Burtnick, M.N. and Woods, D.E. 1999. Molecular Characterization of Genetic Loci Required for Secretion of Exoproducts in *Burkholderia pseudomallei*. *J Bacteriol.* **181**:4661-4664. PMID: 10419967.
55. Woods, D.E., DeShazer, D., Moore, R.A., **Brett, P.J.**, Burtnick, M.N., Recksiedler, S.L. and Senkiw, M. D. 1999. Current Studies on the Pathogenesis of Melioidosis. *Microbes Infect.* **2**:157-162. PMID: 10594980.
56. DeShazer, D., **Brett, P.J.** and Woods, D.E. 1998. The Type II O-Antigen Moiety of *Burkholderia pseudomallei* Lipopolysaccharide is Required for Serum Resistance and Virulence. *Mol Microbiol.* **30**:1081-1100. PMID: 9988483.

57. **Brett, P.J.**, DeShazer, D. and Woods, D.E. 1998. *Burkholderia thailandensis* sp. nov., a *Burkholderia pseudomallei*-Like Species. Int J Syst Bacteriol. **48**:317-320. PMID: 9542103.
58. Ho, M., Schollaardt, T., Smith, M.D., Perry, M.B., **Brett, P.J.**, Chaowagul, W. and Bryan, L.E. 1997. Specificity and Functional Activity of Anti-*Burkholderia pseudomallei* Polysaccharide Antibodies. Infect Immun. **65**:3648-3653. PMID: 9284132.
59. **Brett, P.J.**, DeShazer, D. and Woods, D.E. 1997. Characterization of *Burkholderia pseudomallei* and *Burkholderia pseudomallei*-Like Strains. Epidemiol Infect. **118**:137-148. PMID: 9129590.
60. DeShazer, D., **Brett, P.J.**, Carlyon, R. and Woods, D.E. 1997. Mutagenesis of *Burkholderia pseudomallei* with Tn5-OT182: Isolation of Motility Mutants and Molecular Characterization of the Flagellin Structural Gene. J Bacteriol. **179**:2116-2125. PMID: 9079894.
61. **Brett, P.J.** and Woods, D.E. 1996. Structural and Immunological Characterization of *Burkholderia pseudomallei* O-Polysaccharide-Flagellin Protein Conjugates. Infect Immun. **64**:2824-2828. PMID: 8698517.
62. **Brett, P.J.**, Mah, D. and Woods, D.E. 1994. Characterization of *Pseudomonas pseudomallei* Flagellin Proteins. Infect Immun. **62**:1914-1919. PMID: 7513308.

#### Published Abstracts:

1. Burtnick, M.N., Orne, C.E., Schmidt, L.K., Meadows, L.A., Heiss, C., Azadi, P., Chantratita, N. and **Brett, P.J.** 2019. Optimization of Melioidosis Subunit Vaccines Using *Burkholderia thailandensis* E555. 9th World Melioidosis Congress. Hanoi, Vietnam.
2. Burtnick, M.N., Dance, D.A.B., Vongsouvath, M., Newton, P.N., Davong, V., Kenna, D., Saiprom, N., Wuthiekanun, V., Limmathurotsakul, D., AuCoin, D.P., Chantratita, N., and **Brett, P.J.** 2019. Identification of *Burkholderia cepacia* strains that express a *Burkholderia pseudomallei*-like capsular polysaccharide. 9th World Melioidosis Congress. Hanoi, Vietnam.
3. **Brett, P.J.**, Shaffer, T.L., Schmidt, L.K., Meadows, L.A., Orne, C.E., Wilson, S.M., Khakhum, N., Torres, A.G. and Burtnick, M.N. 2019. Subunit Vaccines Provide Robust Protection Against a High Dose Challenge of *Burkholderia pseudomallei*. 9th World Melioidosis Congress. Hanoi, Vietnam.
4. Orne, C.E., Meadows, L.A., Schmidt, L.K., Burtnick, M.N. and **Brett, P.J.** 2019. Development of Novel Melioidosis Vaccines Using Site-Specific, Single-Point Attachment of CPS to Carrier Proteins. 9th World Melioidosis Congress. Hanoi, Vietnam.

5. Meadows, L.A., Pazar, J.A., Shaffer, T.L., Schmidt, L.K., Orne, C.E., **Brett, P.J.** and Burtnick, M.N. 2019. Evaluation of Recombinant FliC for Use in the Development of Melioidosis Subunit Vaccines. 9th World Melioidosis Congress. Hanoi, Vietnam.
6. Schmidt, L.K., Burtnick, M.N. and **Brett, P.J.** 2019. Use of Bacterial Cell Surface Labeling to Identify New Melioidosis Vaccine Candidates. 9th World Melioidosis Congress. Hanoi, Vietnam.
7. Thamdib, A., Khulthornnaruphan, B., **Brett, P.J.**, Burtnick, M.N., Lertmemongkolchai, G. and Chantratita N. 2019. Analysis of Marketed Rapid Immunochromatography Point-of-Care Test for Serological Diagnosis of Melioidosis in Thailand. 9th World Melioidosis Congress. Hanoi, Vietnam.
8. Pumpuang, A., Phunpang, R., Ekchariyawat, P., Dulsuk, A., Loupha, S., Kwawong, K., Charoensawat, Y., Thiansukhon, E., P.J. Day, N.P.J., Burtnick, M.N., **Brett, P.J.**, West, T.E., Chantratita, N. 2019. Distinct Classes and Subclasses of Antibodies to Hemolysin Co-Regulated Protein 1 and O-polysaccharide and Correlation with Clinical Characteristics of Melioidosis Patients. 9th World Melioidosis Congress. Hanoi, Vietnam.
9. Chaichana, P., Wongwiwat, W., Jenjaroen, K., Burtnick, M.N., **Brett, P.J.**, Limmathurotsakul, D., Day, N.P.J., Mongkolsapaya, J., Sreaton, G., Dunachie, S. 2019. Identification of Protective Antibody Profiles for Vaccine Development Against Melioidosis. 9th World Melioidosis Congress. Hanoi, Vietnam.
10. Green, H.R, Chung, C., Sorenson, J.T., Hau, D., Hannah, E.E., DeMers, H.L., Pandit, S.G., Thorkildson, P.N., Gates-Hollingsworth, M.A., Burtnick, M.N., **Brett, P.J.**, Woerle, C., Mayo, M., Currie, B.J., Woods, K., Luangraj, M., Boutthasavong, L., Davong, V., Dance, D.A.B. and AuCoin, D.P. Quantification of Capsular Polysaccharide in Melioidosis Samples and the Enhancement of the Active Melioidosis Detect Lateral Flow Immunoassay. 9th World Melioidosis Congress. Hanoi, Vietnam.
11. Burtnick, M.N., Orne, C.E., Schmidt, L.K., Meadows, L.A., Heiss, C., Azadi, P., Chantratita, N. and **Paul J. Brett**. 2019. Optimization of Melioidosis Subunit Vaccines Using *Burkholderia thailandensis* E555. VALIDATE-BSI 2019 Conference. London, England.
12. Schmidt, L.K., Quilici, D.R., Burtnick, M.N. and **Brett, P.J.** 2019. Use of Bacterial Cell Surface Labeling to Identify New Melioidosis Vaccine Candidates. UNR Molecular Biosciences Symposium, Reno, NV, USA.
13. Orne, C.E., Meadows, L.A., Schmidt, L.K., Burtnick, M.N. and **Brett, P.J.** 2019. Development of Novel Melioidosis Vaccines Using Site-Specific, Single-Point Attachment of CPS to Carrier Proteins. UNR Molecular Biosciences Symposium, Reno, NV, USA.
14. Pazar, J.A., Shaffer, T.L., Schmidt, L.K., Meadows, L.A., Orne, C.E., Burtnick, M.N. and **Brett, P.J.** 2019. Evaluation of Recombinant FliC for Use in the Development of



Melioidosis Subunit Vaccines. UNR Biotechnology BS/MS Program 15th Annual Biotechnology Symposium. Reno, NV, USA.

15. Pumpuang, A., Phunpang, R., Ekchariyawat, P., Dulsuk, A., Loupha, S., Thiansukhon, E., Burtnick, M.N., **Brett, P.J.**, West, T.E. and Chantratita, N. 2018. Distinct Classes and Subclasses of Human Antibody Responses to Hemolysin Co-Regulated Protein 1 and O-Polysaccharide of *Burkholderia pseudomallei* in Melioidosis Patients. Federation of Immunological Societies of Asia-Oceania Congress, Bangkok, Thailand.
16. Schmidt, L.K., Woosley, R.J., Quilici, D.R., Burtnick, M.N. and **Brett, P.J.** 2018. Use of Bacterial Cell Surface Labeling to Identify Novel New Melioidosis Vaccine Candidates. UNR Molecular Biosciences Symposium, Reno, NV.
17. Koosakulnirand, S., Ekchariyawat, P., Roberts, R.A., Burtnick, M.N., **Brett, P.J.** and Chantratita, N. 2018. Human Innate Immune Response to Recombinant Flagellin of *Burkholderia pseudomallei*. European Melioidosis Congress, Oxford, UK.
18. Phokrai, P., Paksanont, S., Koosakulnirand, S., Saiprom, N., Bancroft, G.J., **Brett, P.J.**, Burtnick, M.N., Lertmemongkolchai, G. and Chantratita, N. 2017. Innovation for Diagnosis of Melioidosis. Joint International Tropical Medicine Meeting. Bangkok, Thailand.
19. Burtnick M.N., Shaffer T.L., Ross B.N., Muruato L.A., Sbrana E., DeShazer D., Torres A.G. and **Brett P.J.** Identifying Correlates of Vaccine-Induced Immunity Using Murine Models of Acute Melioidosis. 2017. Chemical and Biological Defense Science & Technology Conference. Long Beach, CA, USA.
20. Koosakulnirand, S., Ekchariyawat, P., Roberts, R.A., Burtnick, M.N., **Brett, P.J.** and Chantratita, N. 2017. Human innate immune response to recombinant flagellin of *Burkholderia pseudomallei*. Newton Fund-International Links Meeting. Bangkok, Thailand.
21. Nualnoi, T., Kiro Singh, A., Kinney, H., Pandit, S.G., Thorkildson, P., **Brett, P.J.**, Burtnick, M.N., Houghton, R.L. and AuCoin, D.P. 2016. *Burkholderia pseudomallei* capsular polysaccharide: expression, in vivo distribution and detection. 8th World Melioidosis Congress, Cebu, Philippines.
22. Schully, K.L., Bell, M.G., **Brett, P.J.**, Burtnick, M.N., Currie, B.J., Mayo, M., Clark, D.V. and Lawler, J.V. 2016. Serological evidence of exposure to *Burkholderia pseudomallei* in US Marines who train in Darwin Australia: A retrospective analysis. 8th World Melioidosis Congress, Cebu, Philippines.
23. Schully, K.L., Suttisunhakul, V., Hip, P., Ouch, P., Ly, P., Supaprom, C., Rachmat, A., Prouty, M., Vaughn, A., Clark, D.V., Lawler, J.V., Chantratita, N., Burtnick, M.N. and **Brett, P.J.** 2016. Retrospective Analysis of Fever and Sepsis Patients from Cambodia

Reveals Serological Evidence of Melioidosis. 8th World Melioidosis Congress, Cebu, Philippines.

24. Kiroosingh, A., Nualnoi, T., Pandit, S.G., Thorkildson, P., Reed, D.E., **Brett, P.J.**, Burtnick, M.N., AuCoin, D.P. 2016. *In vivo* Clearance and Tissue Distribution of Purified *Burkholderia pseudomallei* Capsular Polysaccharide in a Murine Model. American Society for Microbiology Microbe, Boston, MA, USA.
25. Nualnoi, T., Norris, M.H., Tuanyok, A., **Brett, P.J.**, Burtnick, M.N., Keim, P.S., Settles, E.W., Allender, C.J., AuCoin, D.P. 2016. Development of Immunoassays for *Burkholderia pseudomallei* Typical and Atypical Lipopolysaccharide Strain Typing. American Society for Microbiology Microbe, Boston, MA, USA.
26. Suttisunhakul, V., Wuthiekanun, V., Day, N.P.J., **Brett, P.J.**, Burtnick, M.N., Limmathurotsakul, D. and Chantratita, N. 2015. New Diagnostic Developments for Melioidosis. South Asian Melioidosis Congress, Manipal, India.
27. Suttisunhakul, V., Chantratita, N., Wikraiphath, C., Wuthiekanun, V., Douglas, Z., Day, N. P. J., Limmathurotsakul, D., **Brett, P.J.** and Burtnick, M.N. 2015. Evaluation of Polysaccharide-Based Latex Agglutination Assays for the Rapid Diagnosis of Melioidosis. American Society for Microbiology Annual General Meeting, New Orleans, LA, USA.
28. Burtnick, M.N., Heiss, C., Wikraiphath, C., Roberts, R.A., Azadi, P., Chantratita, N. and **Brett, P.J.** 2015. Identification of Epitopes Recognized by *Burkholderia pseudomallei* and *Burkholderia mallei* O-Polysaccharide Specific Monoclonal Antibodies. American Society for Microbiology Annual General Meeting, New Orleans, LA, USA.
29. Douglas, Z., Burtnick, M.N., Wikraiphath, C., Chantratita, N. and **Brett, P.J.** Development of Polysaccharide-Based Serodiagnostic Assays for Human Melioidosis. 2015. American Thoracic Society 2015 International Conference, Denver, CO, USA.
30. Burtnick, M.N., Heiss, C., Wikraiphath, C., Roberts, R.A., Azadi, P., Chantratita, N. and **Brett, P.J.** 2015. Detailed Analysis of *Burkholderia pseudomallei* O-Polysaccharide Mutants Reveals the Existence of a Third O-Acetyltransferase. European Melioidosis Congress. Cambridge, UK.
31. Burtnick, M.N. and **Brett, P.J.** 2014. Insights into the Complex Regulation of a Virulence Associated Type VI Secretion System Expressed by *Burkholderia pseudomallei*. International Medical Sciences Conference 2014. Khon Kaen, Thailand.
32. Burtnick, M and **Brett, P.** 2014. Insights into the Complex Regulation of *Burkholderia mallei* Virulence Gene Expression. Melioidosis and Glanders Research Community: *Burkholderia* Antigen Discovery Consortium, Lorton, VA, USA.
33. Scott, A., Stokes, M., Laws, T., Heiss, C., Roberts, R., Azadi, P., Atkins, T., Burtnick, M., Prior, J. and **Brett, P.** 2013. Development of Multivalent Subunit Vaccines for

Immunization Against Melioidosis and Glanders. Pacific Southwest Regional Center of Excellence 9<sup>th</sup> Annual Meeting, Huntington Beach, CA, USA.

34. Burtnick, M. and **Brett, P.** 2013. *Burkholderia mallei* T6SS-1 Gene Expression is Negatively Regulated by Iron and Zinc. Pacific Southwest Regional Center of Excellence 9<sup>th</sup> Annual Meeting, Huntington Beach, CA, USA.
35. **Brett, P.** 2013. Antigenically Defined Vaccines for Immunization Against Melioidosis and Glanders. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
36. **Brett, P.** and Burtnick, M. 2013. *Burkholderia pseudomallei* and *Burkholderia mallei* T6SS-1 Gene Expression is Negatively Regulated by Iron and Zinc. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
37. Brown, K., Qazi, O., Gnanam, A., Gebhard, M., **Brett, P.** and Georgiou, G. 2013. Challenges in Whole Organism Detection of *Burkholderia* Pathogens. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
38. Burtnick, M., Wikraiphat, C., Chantratita, N. and **Brett, P.** 2013. Serodiagnosis of Human Melioidosis Using Rapid Latex Agglutination Assays. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
39. Chantratita, N., Wikraiphat, C., Heiss, C., Saiprom, N., Azadi, P., Burtnick, M., Peacock, S. and **Brett, P.** 2013. Identification of Novel Modifications in *Burkholderia pseudomallei* Lipopolysaccharide. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
40. Heiss, C., Burtnick, M., Black, I., Azadi, P. and **Brett, P.** 2013. Revised Structures for the Predominant O-polysaccharides Expressed by *Burkholderia pseudomallei* and *Burkholderia mallei*. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
41. Scott, A., Stokes, M., Laws, T., Heiss, C., Azadi, P., Atkins, T., Burtnick, M., Prior, J. and **Brett, P.** 2013. Development and Testing of Capsular Polysaccharide Based Vaccines for Immunization Against Melioidosis and Glanders. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
42. AuCoin, D., Houghton, R., Dillon, M., Raychaudhuri, S., Limmathurotsakul, D., Currie, B., Serovich, D., Hoffmaster, A., Duval, B., Reed, D., Chantratita, N., Peacock, S., Bowen, R., **Brett, P.**, Burtnick, M. and Kozel, T. 2013. Optimization of a Lateral Flow Immunoassay. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
43. Dillon, M., Reed, D., Houghton, R., Raychaudhuri, S., Chen, J., **Brett, P.**, Burtnick, M., and AuCoin, D. 2013. Development of a mAb Library Targeting the Capsular Polysaccharide of *Burkholderia pseudomallei*. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.

44. Burtnick, M.N. and **Brett, P.J.** 2013. *Burkholderia mallei* and *Burkholderia pseudomallei* T6SS-1 Gene Expression is Negatively Regulated by Divalent Cations. American Society for Microbiology 113<sup>th</sup> General Meeting. Denver, CO, USA.
45. Scott, A.E., Stokes, M.G., Laws, T.R., Atkins, T.P., Burtnick, M.N., Prior, J.L. and **Brett, P.J.** 2013. Active Immunization Against Melioidosis Using CPS-Based Glycoconjugates. Regional Centers of Excellence National Meeting, Seattle, WA, USA.
46. Houghton, R.L., Raychaudhuri, S., Limmathurotsakul, D., Currie, B.J., Hoffmaster, A.R., Duval, B.D., Nuti, D.E., Chantratita, N., Peacock, S.J., Bowen, R., **Brett, P.J.**, Burtnick, M.N., Kozel, T.R. and AuCoin, D.P. 2013. Optimization of a Lateral Flow immunoassay (LFI) for the Rapid Diagnosis of Melioidosis. Regional Centers of Excellence National Meeting, Seattle, WA, USA.
47. Burtnick, M.N. and **Brett, P.J.** 2013. Divalent Cations Negatively Regulate T6SS-1 Gene Expression in *Burkholderia mallei* and *Burkholderia pseudomallei*. Regional Centers of Excellence National Meeting, Seattle, WA, USA.
48. Burtnick, M.N., Wikraiphath, C., Chantratita, N. and **Brett, P.J.** 2013. Serodiagnosis of Human Melioidosis Using Rapid Latex Agglutination Assays. 11<sup>th</sup> Annual ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC, USA.
49. AuCoin, D., Dillon, M., Raychaudhuri, S., Chen, J., Limmathurotsakul, D., Currie, B.J., Hoffmaster, A.R., Duval, B.D., Reed, D.E., Chantratita, N., Peacock, S.J., Bowen, R., **Brett, P.J.**, Burtnick, M.N., Kozel, T.R. and Houghton, R.L. 2013. Optimization of a Lateral Flow Immunoassay (LFI) for the Rapid Diagnosis of Melioidosis. 11<sup>th</sup> Annual ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC, USA.
50. Dillon, M., Nuti, D.E., **Brett, P.J.**, Burtnick, M.N. and AuCoin, D.P. 2012. Development of a mAb Library Targeting the Capsular Polysaccharide of *Burkholderia pseudomallei*. Pacific Southwest Regional Center of Excellence Annual General Meeting, Olympic Valley, CA, USA.
51. Burtnick, M.N., Heiss, C., Roberts, R.A., Azadi, P. and **Brett, P.J.** 2012. Development of Capsular Polysaccharide-Based Glycoconjugates for Immunization Against Melioidosis and Glanders. Pacific Southwest Regional Center of Excellence Annual General Meeting, Olympic Valley, CA, USA.
52. Heiss, C., Burtnick, M.N., Wang, Z., Azadi, P., and **Brett, P.J.** 2012. *Burkholderia mallei* and *Burkholderia pseudomallei* Co-Express Two Unique Homopolymeric Capsular Polysaccharides. Banff Conference on Infectious Diseases, Banff, AB, Canada.
53. **Brett, P.J.**, Gherardini, F.C. and Burtnick, M.N. 2012. Interactions of *Burkholderia pseudomallei* Type III Secretion Mutants with Murine Macrophages. Banff Conference on Infectious Diseases, Banff, AB, Canada.

54. Reed, D., Chantratita, N., Peacock, S.J., Burtnick, M.N., **Brett, P.J.**, Raychaudhuri, S., Houghton, R., Kozel, T.R. and AuCoin, D.P. 2012. Construction of a Lateral Flow Immunoassay for the Diagnosis of Melioidosis. 10<sup>th</sup> Annual ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC, USA.
55. Heiss, C., Burtnick, M.N., Wang, Z., Azadi, P. and **Brett, P.J.** 2012. Structural Analysis of Capsular Polysaccharides Expressed by *Burkholderia mallei* and *Burkholderia pseudomallei*. European Melioidosis Network Meeting. Amsterdam, Netherlands.
56. Nuti, D.E., Crump, R.B., Handayani, F.D., Chantratita, N., Peacock, S.J., Bowen, R., Felgner, P.L., Davies, D.H., Wu, T., Lyons, C.R., **Brett, P.J.**, Burtnick, M.N., Kozel, T.R. and AuCoin, D.P. 2012. Antigen-capture immunoassay for the diagnosis of melioidosis. European Melioidosis Network Meeting. Amsterdam, Netherlands.
57. Burtnick, M.N, Rocker, J.M., Pannell, L.K., DeShazer, D. and **Brett, P.J.** 2011. Molecular Characterization of a Virulence-Associated Type VI Secretion System Expressed by *Burkholderia thailandensis*. American Society for Microbiology Annual General Meeting, New Orleans, LA, USA.
58. **Brett, P.J.**, Gherardini, F.C. and Burtnick, M.N. 2011. *Burkholderia pseudomallei* Cluster 2 and 3 Type III Secretion Systems are Required for Optimal Activation of RAW 264.7 Cells. American Society for Microbiology Annual General Meeting, New Orleans, LA, USA.
59. DeShazer, D. Burtnick, M.N., **Brett, P.J.**, Harding, S.V., Ngugi, S., Ribot, W.J., Chantratita, N., Scorpio, A., Milne, T.S., Dean, R., Fritz, D.L., Peacock, S.J., Prior, J.L. and Atkins, T.P. 2010. The Cluster 1 Type VI Secretion System is a Major Virulence Determinant in *Burkholderia pseudomallei*. 6<sup>th</sup> International Congress on Melioidosis, Townsville, QLD, Australia.
60. Burtnick, M.N, Gherardini, F.C. and **Brett, P.J.** 2010. OacA is Required for the 4-O-Acetylation of *Burkholderia pseudomallei* and *Burkholderia thailandensis* O-Polysaccharides. 6<sup>th</sup> International Congress on Melioidosis, Townsville, QLD, Australia.
61. Burtnick, M.N, Gherardini, F.C. and **Brett, P.J.** 2010. *Burkholderia pseudomallei* Type III Secretion Mutants Differentially Activate RAW 264.7 Macrophages. 6<sup>th</sup> International Congress on Melioidosis, Townsville, QLD, Australia.
62. Burtnick, M.N., **Brett, P.J.**, Deshazer, D., Nair V. and Gherardini, F.C. 2009. *Burkholderia mallei* Cluster 1 Type VI Secretion Mutants Exhibit Replication and Actin-Motility Defects in RAW 264.7 Murine Macrophages. American Society for Microbiology Annual General Meeting, Philadelphia, PA, USA.
63. Burtnick, M.N., **Brett, P.J.** and Gherardini, F.C. 2008. Development of an *Escherichia coli* Reporter System to Investigate Putative Signals Sensed by *Borrelia burgdorferi* Hk2. The Gordon Research Conference on the Biology of Spirochetes. Ventura, CA, USA.

64. **Brett, P.J.**, Burtnick, M.N., Nair, V. and Gherardini, F.C. 2007. *Burkholderia pseudomallei* *bsaZ* is Not Required for Survival and Vacuolar Escape in Activated RAW 264.7 Macrophages. 5<sup>th</sup> World Melioidosis Congress, Khon Kaen, Thailand.
65. **Brett, P.J.**, Burtnick, M.N., Su, H. and Gherardini, F.C. 2007. iNOS Activity is Critical for the Clearance of *Burkholderia mallei* from Infected RAW 264.7 Murine Macrophages. American Society for Microbiology Annual General Meeting, Toronto, ON, Canada.
66. Burtnick, M.N., Downey, J.S., **Brett, P.J.**, Boylan, J.A., Hoover, T.R. and Gherardini, F.C. 2007. Impact of *Borrelia burgdorferi* *hk2* Null Mutations on *rpoS* and *ospC* Expression. American Society for Microbiology Annual General Meeting, Toronto, ON, Canada.
67. **Brett, P.J.**, Burtnick, M.N., Snyder, D.S., Shannon, J.G., Azadi, P. and Gherardini, F.C. 2006. *Burkholderia mallei* LPS is a Potent Activator of Human and Murine Antigen Presenting Cells. SLB/IEIIS Joint Meeting. San Antonio, TX, USA.
68. Burtnick, M.N., Treglown-Downey, J., Boylan, J.A., **Brett, P.J.**, Frye, J., Hoover, T.R. and Gherardini, F.C. 2006. *Borrelia burgdorferi* response regulator Rrp2 activates  $\sigma^{54}$ -dependant *rpoS* expression in an enhancer-independent manner. The Gordon Research Conference on the Biology of Spirochetes. Il Ciocco, Barga, Italy.
69. **Brett, P.J.**, Burtnick, M.N. and Gherardini, F.C. 2005. TroR from *Treponema denticola* is an Iron and Manganese-Dependent Transcriptional Repressor. American Society for Microbiology Annual General Meeting, Atlanta, GA, USA.
70. **Brett, P.J.**, Burtnick, M.N., Woods, D.E. and Gherardini, F.C. 2005. A *Burkholderia thailandensis* O-Polysaccharide Mutant Facilitates the Production of a *Burkholderia mallei* Vaccine Candidate. 1<sup>st</sup> Annual ASM Biodefense and Emerging Diseases Research Meeting. Baltimore, MA, USA.
71. **Brett, P.**, Nie, Z., Liu, J., Margosiak, S., Gajiwala, K. and Su, Y. 2003.  $\beta$ -Ketoacyl-Acyl Carrier Protein Synthase III (FabH): An Attractive Target for the Development of Novel Antibiotics. ICAAC, Chicago, IL, USA.
72. **Brett, P.J.**, Vasu, S.K., Grant, C.C.R., Levin, J.C. and McKenzie, D.T. 2002. Characterization of 5'-Methylthioadenosine Nucleosidase/S-Adenosylhomocysteine Nucleosidase (Pfs) Mutant Phenotypes in Pathogenic and Non-Pathogenic Bacteria. ICAAC, San Diego, CA, USA.
73. Woods, D.E., Tom, M., Moore, R.A., Burtnick, M.N., **Brett, P.J.**, Recksiedler, S.L., Tribuddharat, C. and Ling, J.M. 2001. Studies on the Pathogenesis of Melioidosis. Australian Society for Microbiology Annual Scientific Meeting and Exhibition, Perth, Australia.
74. Burtnick, M.N., **Brett, P.J.** and Woods, D.E. 2001. Physical and Molecular Characterization of an O-antigen Trans-Acetylase Activity in Pathogenic and Non-

- Pathogenic *Burkholderia* spp. American Society for Microbiology Annual General Meeting, Orlando, FL, USA.
75. **Brett, P.J.**, Feavers, I.M. and Charalambous, B.M. 2000. Structurally Constrained Peptide Mimics of Meningococcal Lipooligosaccharide. Twelfth International Pathogenic *Neisseria* Conference, Galveston, TX, USA.
  76. Tzitzilonis, C., **Brett, P.J.**, Feavers, I.M., Lian, L.Y., Derrick, J.P. and Charalambous, B.M. 2000. Mimotopes of *N. meningitidis* Serogroup B Capsular Polysaccharide. Twelfth International Pathogenic *Neisseria* Conference, Galveston, TX, USA.
  77. **Brett, P.J.**, Charalambous, B.M. and Feavers, I.M. 2000. Identification and Characterization of Peptides that Mimic the Epitope Recognized by the *Neisseria meningitidis* Immunotyping Monoclonal Antibody 9-2-L3,7,9. Society for General Microbiology Annual General Meeting, Warwickshire, UK.
  78. Burtnick, M.N., **Brett, P.J.** and Woods, D.E. 1999. Molecular Cloning of an Acid Phosphatase Gene Homolog in *Burkholderia pseudomallei*. Canadian Bacterial Diseases Network Annual General Meeting, Banff, AB, Canada.
  79. Leung, B., **Brett, P.J.** and Woods, D.E. 1999. *Burkholderia pseudomallei* Flagellin Expression and Potential as a Vaccine Candidate. Canadian Society for Microbiologists Annual General Meeting, Montreal, QC, Canada.
  80. **Brett, P.J.**, DeShazer, D. and Woods, D.E. 1998 Self-Cloning Antibiotic Resistance Cassettes: Construction and Applications. UA/UC Conference on Infectious Diseases, Banff, AB, Canada.
  81. DeShazer, D., **Brett, P.J.** and Woods, D.E. 1997. The Type II O-antigen Moiety of *Burkholderia pseudomallei* LPS is Required for Serum Resistance and Virulence. Canadian Bacterial Diseases Network Annual General Meeting, Montebello, QC, Canada.
  82. **Brett, P.J.**, DeShazer, D. and Woods, D.E. 1996. *Burkholderia pseudomallei* Strains Associated with Differential Virulence in Hamsters. American Society for Microbiology Annual General Meeting, New Orleans, LA, USA.
  83. DeShazer, D., **Brett, P.J.** and Woods, D.E. 1996 Mutagenesis of *Burkholderia pseudomallei* with Tn5-OT182: Characterization of Mutants Deficient in Protease, Lipase and Lecithinase. American Society for Microbiology Annual General Meeting, New Orleans, LA, USA.
  84. **Brett, P.J.**, Bryan, L.E., Perry, M.B. and Woods, D.E. 1994. Construction of a Lipopolysaccharide-Flagellin Conjugate Immunogen for Protection Against *Pseudomonas pseudomallei*. American Society for Microbiology Annual General Meeting, Las Vegas, NV, USA.

85. **Brett, P.J.** and Woods, D.E. 1993. Isolation and Characterization of *Pseudomonas pseudomallei* Flagellin Protein for Use as a Potential Vaccine Candidate. 4th International Symposium on *Pseudomonas*: Biotechnology and Molecular Biology, Vancouver, BC, Canada.

### Book Chapters:

1. **Brett, P.J.**, DeShazer, D. and Vietri, N. *Melioidosis*. 2018. In: Textbooks of Military Medicine: Medical Aspects of Biological Warfare. Bozue, J., Cote, C.K. and Glass, P.J. (eds.) Borden Institute, pp. 223-246.
2. Audia, J.P., Burtnick, M.N. and **Brett, P.J.** 2012. *Burkholderia thailandensis*. In: *Melioidosis: A Century of Observation and Research*. Ketheesan, N. (ed.). Elsevier, pp. 380-390.
3. Ramsey, D.M., **Brett, P.J.** and Burtnick, M.N. 2012. *Burkholderia mallei*. In: *Melioidosis: A Century of Observation and Research*. Ketheesan, N. (ed.). Elsevier, pp. 391-403.
4. Gherardini, F.C., Boylan, J.A. and **Brett, P.J.** 2006. *Metal Utilization and Oxidative Stress*. In: *Pathogenic Treponema - Molecular and Cellular Biology*. Radolf, J.D. and Lukehart, S.A. (eds.). Caister Academic Press, pp.101-126.
5. Burtnick, M.N., **Brett, P.J.** and Woods, D.E. 2002. *Identification of Genes Encoding Secreted Proteins Using Mini-OphoA Mutagenesis*. In: *Methods in Molecular Biology - E. coli Gene Expression Protocols*. Vaillancourt, P.E. (ed.). Humana Press, pp. 329-338.
6. **Brett, P.J.**, Feavers, I.M. and Charalambous, B.M. 2001. *Identification of Peptides that Mimic N. meningitidis LOS Epitopes Via the Use of Combinatorial Phage-Display Libraries*. In: *Meningococcal Vaccines - Methods and Protocols*. Pollard, A.J. and Maiden, M.C.J. (eds.). Humana Press, pp. 181-197.

### INVITED PRESENTATIONS:

1. *Melioidosis Subunit Vaccines: Recent Developments and Future Directions*. 2020. Joint International Tropical Medicine Meeting 2020 (JITMM Virtual 2020). Bangkok, Thailand.
2. *Melioidosis Subunit Vaccines: Recent Developments and Future Directions*. 2020. Biochemistry Seminar Series. University of Nevada, Reno, NV.
3. *Melioidosis Subunit Vaccines: Recent Developments and Future Directions*. 2020. ASM Biothreats Meeting, Arlington, VA.
4. *Tips for writing a research grant*. Proposal Writing Workshop for TropMed Researchers. 2020. Faculty of Tropical Medicine, Mahidol University, Nakhon Ratchasima, Thailand.



5. Subunit Vaccines Provide Robust Protection Against a High Dose Challenge of *Burkholderia pseudomallei*. 2019. 9<sup>th</sup> World Melioidosis Congress, Hanoi, Vietnam.
6. Development of Multivalent Subunit Vaccines for Immunization Against Melioidosis. 2019. VALIDATE-BSI 2019 Conference. London, England.
7. Melioidosis Vaccine Candidates: Moving from Animal Models to Man. 2019. The Jenner Institute, Oxford, UK.
8. Development of Subunit Vaccines for Immunization Against Melioidosis. 2019. The Jenner Institute, Oxford, UK.
9. Optimization of Glycoconjugate Vaccines for Immunization Against Melioidosis. 2018. Mahidol University. Bangkok, Thailand.
10. Optimization of Glycoconjugate Vaccines for Immunization Against Melioidosis. 2018. Joint International Tropical Medicine Meeting. Bangkok, Thailand.
11. Development and Testing of Melioidosis and Glanders Subunit Vaccines. 2018. Biomedical Advanced Research and Development Authority Techwatch Program. Washington, D.C., USA.
12. Melioidosis and Glanders: Aspects of Pathogenesis and Immunity. 2018. University of Texas Medical Branch, Galveston, TX.
13. Subunit Vaccines Provide Robust Protection Against Acute Inhalational Melioidosis. 2018. European Melioidosis Congress, Oxford, UK.
14. Subunit Vaccines Provide Robust Protection Against Acute Inhalational Melioidosis. 2018. Myanmar Military Medical Conference, Yangon, Myanmar.
15. Development of a Multivalent Subunit Vaccine That Provides Sterilizing Immunity Against Melioidosis. 2017. Joint International Tropical Medicine Meeting. Bangkok, Thailand.
16. Identifying Correlates of Vaccine-Induced Immunity Using Murine Models of Acute Melioidosis. 2017. Newton Fund-International Links Meeting. Bangkok, Thailand.
17. Identification of Minimal Epitopes Recognized by Protective OPS-Specific Monoclonal Antibodies: Implications for Vaccine Development. 2016. 8<sup>th</sup> World Melioidosis Congress, Cebu, Philippines.
18. Development of Subunit Vaccines for Immunization Against Melioidosis. 2016. University of Nevada, Reno, NV, USA.

19. Pathogenesis and Treatment of Melioidosis. 2015. Nay Pyi Taw General Hospital. Nay Pyi Taw, Myanmar.
20. Pathogenesis and Treatment of Melioidosis. 2015. Defence Services Medical Research Center. Nay Pyi Taw, Myanmar.
21. Pathogenesis and Treatment of Melioidosis. 2015. National Blood Center. Yangon, Myanmar.
22. Importance of Adjuvants in the Development of Melioidosis Subunit Vaccine Formulations. 2015. European Melioidosis Congress. Cambridge, UK.
23. Antigenically Defined Vaccines for Immunization Against Melioidosis and Glanders. 2015. ASM Biodefense and Emerging Diseases Research Meeting. Washington, DC, USA.
24. Antigenically Defined Vaccines for Immunization Against Melioidosis. 2014. UTMB, Galveston, TX, USA.
25. Antigenically Defined Vaccines for Immunization Against Melioidosis. 2014. University of Toledo, Toledo, OH, USA.
26. Antigenically Defined Vaccines for Immunization Against Melioidosis and Glanders. 2014. 100th Annual ASM Southeastern Branch Conference. Ponte Vedra Beach, FL, USA.
27. Glycoconjugate Vaccine Induced Immunity Against Melioidosis. 2014. International Medical Sciences Conference 2014, Khon Kaen, Thailand.
28. Animal Models for Vaccine Development. 2014. Preconference course: Update on infection, immunity and vaccines during the International Medical Sciences Conference 2014, Khon Kaen, Thailand.
29. Antigenically Defined Vaccines for Immunization Against Melioidosis and Glanders. 2014. Melioidosis and Glanders Research Community: *Burkholderia* Antigen Discovery Consortium, Lorton, VA, USA.
30. Development of Polysaccharide-Based Vaccines for Immunization Against Melioidosis. 2014. University of Victoria, Victoria, BC, Canada.
31. Antigenically Defined Vaccines for Immunization Against Melioidosis and Glanders. 2013. 7<sup>th</sup> World Melioidosis Congress, Bangkok, Thailand.
32. Development of Diagnostic Tools Using *B. pseudomallei* Polysaccharides. 2013. Centers for Disease Control and Prevention: Melioidosis Diagnostics Workshop. Bangkok, Thailand.

33. Novel Strategies for the Prevention, Diagnosis and Treatment of Melioidosis and Glanders. 2013. Defense Threat Reduction Agency Chemical and Biodefense Tech Watch Platform, Fort Belvoir, VA, USA.
34. Development of Glycoconjugate Vaccines for Immunization Against Melioidosis and Glanders. 2012. Pacific Southwest Regional Center of Excellence Annual General Meeting, Olympic Valley, CA, USA.
35. Molecular Insights Into the Pathogenesis of Melioidosis and Glanders. 2012. Rocky Mountain Laboratories, NIAID, NIH, Hamilton, MT, USA.
36. Molecular Insights Into the Pathogenesis of Melioidosis and Glanders. 2012. Banff Conference on Infectious Diseases, Banff, AB, Canada.
37. Development of Glycoconjugate Vaccines for Immunization Glanders. 2012. University of South Dakota, Vermillion, SD, USA.
38. Development of Glycoconjugate Vaccines for Immunization Glanders. 2012. Defence Science and Technology Laboratory, Salisbury, United Kingdom.
39. Development of Glycoconjugate Vaccines for Immunization Against Melioidosis and Glanders. 2012. University of Leicester, Leicester, United Kingdom.
40. Development of Glycoconjugate Vaccines for Immunization Against Melioidosis and Glanders. 2011. Keim Genetics Laboratory/US Department of Homeland Security *Burkholderia* Workshop. Flagstaff, AZ, USA.
41. Interactions of *Burkholderia mallei* with Murine Macrophages. 2010. Mitchell Cancer Institute, Mobile, AL, USA.
42. Interactions of *Burkholderia mallei* with Murine Macrophages. 2010. University of Georgia, Athens, GA, USA.
43. Interactions of *Burkholderia pseudomallei* with Murine Macrophages. 2009. Ninety-Fifth Annual ASM Southeastern Branch Conference. Savannah, GA, USA.
44. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. University of Kansas Medical Center, Kansas City, KS, USA.
45. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. University of Adelaide, Adelaide, SA, Australia.
46. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. University of Texas at El Paso, El Paso, TX, USA.

47. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. University of Texas at San Antonio, San Antonio, TX, USA.
48. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. University of South Alabama, Mobile, AL, USA.
49. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. University of Texas at Houston, Houston, TX, USA.
50. Interactions of *Burkholderia mallei* with Murine Macrophages. 2008. Montana State University, Bozeman, MT, USA.
51. *Burkholderia pseudomallei bsaZ* is Not Required for Survival and Vacuolar Escape in Activated RAW 264.7 Macrophages. 2007. 5<sup>th</sup> International Congress on Melioidosis, Khon Kaen, Thailand.
52. *Burkholderia mallei* LPS: Structure/Function Analysis of an Atypical TLR4 Agonist. 2006. GlaxoSmithKline Biologicals, Hamilton, MT, USA.
53. Molecular Characterization of *Burkholderia pseudomallei* Lipopolysaccharide Mutants. 2005. University of Alberta, Edmonton, AB, Canada.
54. Molecular Characterization of *Burkholderia pseudomallei* Lipopolysaccharide Mutants. 2005. Texas A&M University, College Station, TX, USA.
55. Molecular Characterization of *Burkholderia pseudomallei* Lipopolysaccharide Mutants. 2005. Medical College of Ohio, Toledo, OH, USA.
56. Vaccine Strategies Against Melioidosis and Glanders. 2003. Rocky Mountain Laboratories, Hamilton, MT, USA.
57. Vaccine Strategies Against Meningococcal Meningitis and Glanders. 2003. University of Guelph, Guelph, ON, Canada.
58. Career Opportunities for Microbiology Graduates. 2002. University of Calgary, Calgary, AB, Canada.
59. Vaccine Strategies Against Meningococcal Meningitis. 2001. Quorex Pharmaceuticals Inc., Carlsbad, CA, USA.
60. Vaccine Strategies for Immunoprophylaxis Against Melioidosis. 1998. International Congress on Melioidosis, Bangkok, Thailand.
61. Immunoprophylaxis Against Melioidosis. 1998. Harvard Medical School, Boston, MA, USA.

62. Immunoprophylaxis Against Melioidosis. 1998. Eli Lilly, Indianapolis, IN, USA.
63. Type II Lipopolysaccharide is Correlated with Virulence and Serum Resistance in *Burkholderia pseudomallei*. 1997. Canadian Society for Microbiologists Annual General Meeting, Quebec City, QC, Canada.

**RESEARCH SUPPORT:****Pending:**

DTRA STN1-17-TA1-1-0042 Fischer (PI)  
 7/2021 - 6/2026  
 Formulating and evaluating nanolipoprotein particle-based multi-pathogen vaccines  
 Role: Subaward Co-PI  
 Total Direct costs: \$950,000

**Current:**

MR/T025611/1 Dunachie (PI)  
 \*Anticipated 2021-2024  
 Developing a Vaccine for *Burkholderia pseudomallei* - a Phase I Clinical Trial  
 Role: Co-I (Brett)  
 Award Amount: \$1,800,000  
 \*Grant will be activated when the GMP production of our vaccines antigens is complete

HDTRA1-21-C-0014 Brett (PI)  
 1/26/2021 - 1/25/2025  
 Analysis of Bacterial Isolates and Tissue Specimens from Thai and Burmese Melioidosis Patients  
 Total Direct costs: \$3,116,415

MCDC-18-04-11-004 Burtnick (PI)  
 9/12/2019 – 9/30/2023  
 Development of Standardized Assays to Identify Molecular Signatures of *Burkholderia* Vaccine-Induced Immunity  
 Role: Co-PI (Brett)  
 Total Direct Costs: \$1,906,220

HDTRA1-18-C-0062 Brett (PI)  
 09/28/2018 - 09/27/2021  
 Optimization of Lead Melioidosis and Glanders Subunit Vaccine Formulations.  
 Total direct costs: \$3,415,280

**Completed:**

VALIDATE Pump-priming Project Stylianou (PI)  
 2019-2020  
 Developing a Mouse Model of Diabetes to Evaluate Vaccines for TB and Melioidosis  
 Role: Co-PI (Brett)  
 Award Amount: £50,000

HDTRA1620991 Schully (PI)  
 10/2016 - 06/2019  
 Immune Correlates of Protection for *Burkholderia pseudomallei* in a Healthy American Population: A Migratory Cohort Study of US Marines Serving in Darwin Australia.  
 Role: Subaward Co-PI  
 Subaward Direct Costs: \$1,256,248

HDTRA1-14-C-0023 Brett (PI)  
 02/18/2014 - 10/31/2017  
 Antigenically Defined Vaccines for Immunization Against Melioidosis and Glanders.  
 Total direct costs: \$1,365,284

TNPRC (Service Contract) Brett (PI)  
 03/2016 - 06/2017  
 Melioidosis Rapid Latex Agglutination Tests.  
 Total Direct Costs: \$180,000

CBD14-105 (SBIR - Phase II) Kanneganti (PI)  
 05/26/2015 - 05/25/2017  
 High-affinity monoclonal antibodies that target *Burkholderia* polysaccharide.  
 Role: Subaward Co-PI  
 Subaward Direct Costs: \$195,349

TNPRC Brett (PI)  
 03/2015 - 02/2016  
 Melioidosis Rapid Latex Agglutination Tests.  
 Total Direct Costs: \$89,825

CBD14-105 (SBIR - Phase I Option) Hubbard (PI)  
 03/01/2015 - 05/30/2015  
 High-affinity monoclonal antibodies that target *Burkholderia* polysaccharide.  
 Role: Subaward PI  
 Subaward Direct Costs: \$11,038

CBD14-105 (SBIR - Phase I) Hubbard (PI)  
 05/07/2014 - 11/07/2014  
 High-affinity monoclonal antibodies that target *Burkholderia* polysaccharide.  
 Role: Subaward PI  
 Subaward Direct Costs: \$33,113

NIH U54 AI065359 Barbour (PI)  
 05/01/2012 - 04/30/2015  
*Burkholderia mallei* Type VI Secretion System-Associated Effectors.  
 Role: Subaward Co-PI (PSWRCE Developmental Research Project)  
 Total direct costs: \$260,162

NIH R56 AI091783

Brett (PI)

08/01/2011 - 07/31/2014

Analysis of a *Burkholderia mallei* Virulence-Associated Type VI Secretion System.

Total direct costs: \$225,000

NIH R21 AI088418

Brett (PI)

09/01/2010 - 08/31/2012

Development and Testing of Novel Glanders Vaccine Candidates.

Total direct costs: \$275,000